Jan 10, 2024 / 09:30PM GMT
Jessica Fye JPMorgan-Analyst
Great. Good afternoon, everyone. Welcome. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan, and we're continuing the 42nd Annual Healthcare Conference today with Amarin. I'm joined up here by the Company's President and CEO, Pat Holt. He's going to give a presentation on the business, and then we're going to go into Q&A. (Operator Instructions) So with that, let me pass it over to Pat.
Patrick Holt - Amarin Corporation PLC - Non-Executive Independent Director
Thanks, Jess. Good afternoon, everyone. It's wonderful to be with you today. I'm Pat Holt, the President and CEO of Amarin. And Jess, thanks so much for the invitation to join the 42nd Annual JPMorgan Conference. We're delighted to be here.
So 2023 was a really important transitional year for our company. Earlier today, you may have noticed we announced our Q4 preliminary results for 2023, which are really encouraging and demonstrate important progress for our business. As an example, in Europe, based on new leadership and a new strategy, we
Amarin Corporation PLC at JPMorgan Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers